Flunarizine in prevention of headache, ataxia, and memory deficits during decompression to 4559 m.
Our purpose was to study the preventive effect of the calcium channel blocker flunarizine on headache, postural ataxia, and memory deficits occurring during decompression to high altitude in a randomized, placebo-controlled, double-blind study. After 7-day pretreatment with the study drugs, 20 healthy men were investigated at 490 m and 0.5, 2, 4, and 6 h later at a simulated altitude of 4559 m. Headache severity was evaluated on a 4-point scale. Sway path and anteroposterior and lateral sway were recorded with open and closed eyes by static posturography. Short- and long-term memory was studied by testing the recall of verbal and figural material immediately and 2 h after presentation, respectively. Blood pressure (BP) and arterial oxygen saturation (Sa(O2)) were also assessed. Headache scores showed a trend to be lower in the flunarizine group that was significant after 4 and 6 h. Headache scores expressed as difference from baseline values showed a nonsignificant trend to be lower at 4 and 6 h in subjects treated with flunarizine. Postural stance, memory, BP, and Sa(O2) were similar in both treatment groups. Although the low number of investigated subjects may have prevented the detection of a significant therapeutic effect of flunarizine, the present data do not show that flunarizine is effective for prevention of headache, postural ataxia, and neurocognitive deficits occurring at simulated high altitude.
Baumgartner
Ralf W
RW
Neurovascular Division, Department of Neurology, University of Zürich, Frauenklinikstrasse 26, Zürich, Switzerland. ralf.baumgartner@nos.usz.ch
Keller
Sandra
S
Regard
Marianne
M
Bärtsch
Peter
P
D000328:Adult; D000532:Altitude Sickness / Q000150:complications / Q000517:prevention & control; D001259:Ataxia / Q000209:etiology / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D003665:Decompression Sickness / Q000150:complications / Q000517:prevention & control*; D004311:Double-Blind Method; D005444:Flunarizine / Q000627:therapeutic use*; D006261:Headache / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008569:Memory Disorders / Q000209:etiology / Q000517:prevention & control*; D010101:Oxygen Consumption / Q000187:drug effects; D011446:Prospective Studies; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D005444:Flunarizine